香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因本聯合公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何 損 失 承 擔 任 何 責 任。 Pharma Corporation Jacobson Pharma Corporation Limited 雅 各 臣 科 研 製 藥 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2633） JBM (Healthcare) Limited 健倍 苗 苗 ( 保健 ) 有 限 公司 （於開曼群島註冊成立的有限公司） （股份 代號：2161） 聯合公告 有關買賣 李衆勝堂（集 團）有限公司 股份的關連交易 買賣李衆勝堂（集 團）有限公司股份 於二零二四年十一月十一日（交 易 時 段 後），Po Chai Herbal 及 PCHT（作 為 賣 方）與歐化藥業（作 為 買 方）訂 立 買 賣 協 議，據 此，Po Chai Herbal 及 PCHT 有 條 件同意分別出售56,500股 及44,000股 銷 售 ...

（股份代號：2633） 董事會召開日期 雅各臣科研製藥有限公司（「本公司」）董事會（「董事會」）兹通告謹定於二零二四 年十一月二十一日（星 期 四）舉 行 董 事 會 會 議，藉 以 考 慮 及 通 過 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 四 年 九 月 三 十 日 止 的 六 個 月 中 期 業 績 以 供 發 佈，並 考 慮 派 發 中期股息（如 有），以 及 處 理 其 他 事 項。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Pharma Corporation Jacobson Pharma Corporation Limited 雅 各 臣 科 研 製 藥 有 限 公 司 （於開曼群島註冊成立的有限公司） 公司秘書 余振球 香 港，二 零 二 四 年 十 一 月 八 日 於 本 公 告 日 期，董 事 會 由 執 行 董 事 岑 廣 業 先 生（亦 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Pharma Corporation Jacobson Pharma Corporation Limited 雅 各 臣 科 研 製 藥 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2633） 盈喜預告 本公告由雅各臣科研製藥有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） 根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)(a)條及香港 法例第571章證券及期貨條例第XIVA部項下內幕消息條文（定 義 見 上 市 規 則）刊 發。 本公司董事（「董 事」）會（「董事會」）謹此告知本公司股東（「股 東」）及 潛 在 投 資 者， 基於對本集團截至二零二四年九月三十日止六個月（「中期期間」）的未經審核 綜 合 管 理 賬 目 的 初 步 審 閱 及 董 事 會 目 前 可 得 的 資 料，本 ...

財務摘要 0 500,000 1,000,000 1,500,000 2,000,000 2,500,000 3,000,000 3,500,000 二零二一 財年 二零二二 財年 二零二三 財年 二零二四 財年(1) 二零二零 財年 資產淨值 （千港元） 於二零二四年 (3) 來自持續經營業務的經調整EBITDA率根據來自持續經營業務的經調整EBITDA除以來自持續經營業務的收益再乘以100%計算得出。 各位股東： 致力卓越營運 展望未來，儘管我們預期在疫情後將會逐步復甦，但我們深知目前的 地緣政治緊張局勢及動盪對當前的經濟帶來不明朗因素。雖然我們意 識到市場上的種種逆境，但對經濟長期韌性及非專利藥市場以至更廣 泛的醫療保健行業的增長潛力仍然抱持樂觀態度。我們致力在這個日 新月異的時局中培養我們的企業適應力及靈活性，為可持續發展奠下 堅實的基礎。 最後，本人謹代表董事會向我們的僱員、合作夥伴和股東致以衷心的 感謝。你們堅定不移的支持和貢獻，為我們致力提供可及、優質的醫 療解決方案，並為所有持份者創造可持續價值的旅程帶來關鍵助力。 二零二四年六月二十日 | --- | --- | --- | |------- ...

Financial Performance - For the fiscal year ending March 31, 2024, revenue from continuing operations was approximately HKD 1,467.8 million, an increase of about 15.8% compared to HKD 1,267.6 million in the same period of 2023[1]. - Operating profit from continuing operations for the same fiscal year was approximately HKD 333.1 million, up about 17.2% from the adjusted operating profit of HKD 284.3 million in 2023[1]. - Profit for the year was approximately HKD 290.8 million, representing a 14.4% increase from the adjusted profit of HKD 254.1 million in the previous year[1]. - The company's total comprehensive income attributable to equity holders from continuing operations for the year ended March 31, 2024, was HKD 193,815, a decrease of 38.6% compared to HKD 315,570 for the same period in 2023[23]. - The reported segment revenue for the year ended March 31, 2024, was HKD 1,467,814,000, representing an increase of 15.7% compared to HKD 1,267,868,000 for the previous year[64]. - The adjusted EBITDA for the reporting segments was HKD 453,079,000 for the year ended March 31, 2024, compared to HKD 444,173,000 for the previous year, reflecting a growth of 2%[64]. - The company reported a profit attributable to equity holders of HKD 210,236,000 from continuing operations for the year ended March 31, 2024, compared to HKD 207,513,000 for the previous year[70]. - The company’s total comprehensive income for the year ended March 31, 2024, was HKD 254,583,000, compared to HKD 250,345,000 for the previous year, showing a modest increase[65]. - The company’s effective tax rate for the year was maintained at 16.5%, consistent with the previous year[68]. Dividends - The board proposed a final dividend of HKD 0.03 per share, totaling approximately HKD 60.0 million, compared to a final dividend of HKD 0.0238 per share in 2023[1]. - The proposed final dividend per share is HKD 3.00 for the year ended March 31, 2024, compared to HKD 2.38 for the previous year, indicating an increase of 26.1%[74]. - The company distributed a special dividend of 492,259,244 shares of Jianbei Miao Miao, equivalent to approximately HKD 29.52 per share based on the closing price of HKD 1.16 on August 24, 2023[77]. Assets and Liabilities - Non-current assets totaled HKD 2,522.4 million, a decrease from HKD 3,623.1 million in the previous year[5]. - Current assets decreased to HKD 591.6 million from HKD 1,100.98 million in the previous year[5]. - Total equity decreased to HKD 2,396.4 million from HKD 3,256.5 million in the previous year[6]. - Cash and cash equivalents were HKD 411.9 million, down from HKD 1,036.4 million in the previous year[5]. - Non-current liabilities decreased significantly to HKD 717,651 as of March 31, 2024, from HKD 1,467,542 in 2023, a reduction of 51.1%[26]. - The net asset value of the company was HKD 2,396,360 as of March 31, 2024, down from HKD 3,256,522 in 2023, indicating a decline of 26.4%[26]. - The company’s total liabilities decreased to HKD 1,467,542 in 2024 from HKD 2,234,000 in 2023, indicating a reduction of 34.4%[26]. Operations and Market Presence - The company is primarily engaged in the development, production, marketing, and sale of non-patent drugs, with operations mainly in Hong Kong[7]. - The brand healthcare segment's performance has been classified as discontinued operations for the fiscal year ending March 31, 2024[4]. - The company has ceased operations in the brand medical healthcare business, classifying it as a discontinued operation[85]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[67]. - The company is optimistic about future growth, focusing on expanding its product portfolio and enhancing R&D capabilities[94]. - The company is developing an innovative e-business platform tailored for private clinics, which has received positive feedback and shows promising adoption rates[124]. - The company has expanded distribution agreements in selected Southeast Asian countries, including a signed agreement with Malaysia, and is considering clinical trials in the UK, Netherlands, and the US[179]. Research and Development - Research and development costs, excluding capitalized development costs, were HKD 6,450 for the year ended March 31, 2024, compared to HKD 1,166 in 2023, showing a significant increase[44]. - The R&D pipeline includes 185 products at various development stages, with 64 products already registered and 12 submitted for approval[145]. - The company successfully submitted 12 products for approval, enhancing its product pipeline and future market offerings[94]. - The company obtained exclusive rights to six effective specialty drugs across various fields, including gastrointestinal diseases and oncology, enhancing its product portfolio and driving continuous growth[123]. Employee and Operational Costs - Employee costs rose by HKD 42.6 million or 18.0%, reflecting the need for increased production to meet product demand[170]. - The group employed 1,723 employees as of March 31, 2024, compared to 1,484 employees as of March 31, 2023, indicating a strategic increase in workforce[189]. - The group provides various employee benefits, including annual leave, mandatory provident fund, group medical insurance, and life insurance[189]. - The company maintains a strong focus on employee recruitment, development, and retention, offering competitive compensation and training programs[161]. Market Trends and Demand - The demand for basic and specialty pharmaceuticals increased due to the recovery of social activities post-pandemic[105]. - The increase in flu cases, particularly among children and the elderly, has driven demand for cold and flu medications, resulting in growth in both public and private sector businesses during the reporting period[132]. - The aging population with complex health needs is driving the demand for chronic disease management medications, aligning with the value proposition of the non-patent drug market[184]. - The economic recovery in Hong Kong post-COVID-19 has led to a significant increase in inbound tourism and consumer spending, contributing to strong performance since Q1 2023[128]. Strategic Initiatives - The company’s strategic execution has resulted in substantial achievements and effective cost management[122]. - The collaboration with Fosun Kite Biotechnology for the CAR-T cell therapy Yescarta aims to enhance treatment options for specific types of lymphoma[151]. - The initial pilot phase of the medical e-business system has yielded positive results, reflected in good user feedback and excellent adoption rates[181]. - The platform provides unparalleled convenience for medical professionals and key customers, facilitating easy access to the product range and streamlining the ordering process[182].

智通财经APP讯，雅各臣科研制药(02633)发布公告，于2024年2月19日，该公司与配售代理订立配售协议，公司委任配售代理按尽力基准且须满足配售协议的先决条件，按每股配售股份0.60港元的价格向不少于六名独立承配人(或公司与配售代理以书面协定的承配人数目)配售合共6600万股配售股份，每股配售股份的配售价为0.60港元，较2月19日收市价每股0.61港元折让约1.64%，假设配售股份获悉数配售，则最高数目的6600万股配售股份占公司经发行最高数目的配售股份扩大后已发行股本约3.30%。 假设配售股份获悉数分配，则配售所得款项总额将约为3960万港元，所得款项净额预期将约为3880万港元。公司拟动用该等所得款项净额，透过增强生产及包装流程自动化以扩大其生产能力。所得款项净额将主要用作翻新集团生产设施以及购置机器及设备的开支。 ...

Financial Performance - The company reported a significant increase in net profit by HKD 30.5 million or 20.7% to HKD 177.9 million, driven by strong sales and a one-time net gain from the distribution of shares [28]. - Operating profit increased by HKD 2.7 million or 1.7% to HKD 166.0 million, primarily due to increased sales, offset by a decrease in logistics service income and increased operating expenses [25]. - Revenue for the six months ended September 30, 2023, was HKD 714,918,000, an increase from HKD 581,891,000 in the same period of 2022, representing a growth of 22.8% [169]. - Total comprehensive income for the period was HKD 172,685,000, compared to HKD 114,148,000 in the previous year, showing an increase of 51.3% [169]. - Profit for the period increased by HKD 52.6 million or 42.0% after excluding one-time government subsidies [52]. - The group reported a significant increase in bank deposits and investment income, amounting to HKD 218,120,000, compared to HKD 3,287,000 in the previous year [188]. - The group’s profit for the period was HKD 714,918,000, with a reported profit from continuing operations of HKD 242,521,000, compared to HKD 235,462,000 in the prior year, reflecting a slight increase of 3.5% [188]. Cost and Expenses - Employee costs rose by HKD 11.3 million or 9.4%, reflecting the need to increase production to meet rising product demand and to attract and retain production staff [24]. - Sales costs increased by HKD 85.7 million or 26.1%, consistent with overall sales growth, with material costs comprising approximately 44% of total sales costs [44]. - Financing costs surged by HKD 27.9 million or 142.2% due to rising market interest rates during the reporting period [48]. - The total employee cost for the reporting period was HKD 215.4 million, an increase from HKD 182.0 million in the same period last year [19]. - The amortization of intangible assets and depreciation amounted to HKD 10,373,000 for the six months ended September 30, 2023, down from HKD 11,480,000 in the previous year [193]. Business Development and Strategy - The company aims to solidify its position as a leading supplier of essential and specialty drugs in Hong Kong and Asia, focusing on growth strategies [17]. - The company continues to invest in new product development and has engaged external experts to enhance overall R&D capabilities [63]. - The company has successfully integrated Arsenic Trioxide Oral Solution into the prescription list of a major hospital, marking a significant step in its market expansion strategy [14]. - The company is committed to enhancing its business infrastructure, including logistics and regulatory management, supported by an SAP system to improve supply chain efficiency [5]. - The group has successfully completed multiple acquisitions and continues to seek new acquisition opportunities while conducting thorough due diligence [85]. Cash Flow and Financial Position - The cash generated from operating activities for the six months ended September 30, 2023, was HKD 276,336 thousand, a decrease from HKD 307,987 thousand in the same period of 2022, representing a decline of approximately 10.3% [152]. - The total cash and cash equivalents decreased by HKD 411,225 thousand, compared to an increase of HKD 383,121 thousand in the same period of 2022 [152]. - As of September 30, 2023, the cash and cash equivalents amounted to HKD 871,048 thousand, down from HKD 860,409 thousand as of the same date in 2022 [152]. - The net cash used in investing activities for the six months ended September 30, 2023, was HKD 70,205 thousand, compared to a net cash used of HKD 11,467 thousand in the same period of 2022 [152]. - The group has a total of HKD 1,400,000,000 in syndicated loans, with an outstanding balance of HKD 872,000,000 as of the mid-term report date [91]. Regulatory and Compliance - The group has complied with all applicable laws and regulations during the reporting period, with no significant regulatory non-compliance issues [88]. - The company did not apply any new standards or interpretations that have not yet come into effect during the reporting period [156]. - The company’s actual tax rate is higher than the minimum tax rate specified in the OECD's Pillar Two framework, thus the recent tax amendments did not have a significant impact on the financial statements [158]. Shareholder Information - The board declared an interim dividend of HKD 0.025 per share for the six months ending September 30, 2023, totaling approximately HKD 48.4 million, compared to HKD 0.028 per share for the same period in 2022 [121]. - As of September 30, 2023, Mr. Chan holds 1,181,638,000 shares, representing approximately 61.09% of the company's issued share capital [124]. - The company has a significant shareholder structure, with Kingshill holding 850,684,000 shares, accounting for approximately 43.98% of the issued share capital [127]. - The company has not issued any stock options under its stock option plan since its inception, with a total of 37,000,000 options granted but none exercised as of September 30, 2023 [135]. Research and Development - The group has established a new research and development center in collaboration with a biological research institute, with an investment of HKD 5,882,000 [79]. - The company has revised its share award plan on September 21, 2023, to be funded solely by existing shares [139].

企業管治守則的守則條文第C.2.1條 規 定 主 席 與 行 政 總 裁 的 角 色 應 有 區 分，並 不 應 由 一 人 同 時 兼 任。主 席 與 行 政 總 裁 之 間 職 責 的 分 工 應 清 楚 界 定，並 以 書 面 形 式 列 載。 進行證券交易的標準守則 購 買、出 售 或 贖 回 上 市 證 券 審核委員會及本公司管理層亦已審閱截至二零二三年九月三十日止六個月的 中 期 業 績。 暫停辦理股東登記手續 | --- | --- | --- | --- | |-------|-------|-------|------------------------| | | | | | | | | | 承董事會命 | | | | | 雅各臣科研製藥有限公司 | | | | | 執行董事 | | | | | 嚴振亮 | 詞 彙 – 38 – 「健 倍 苗 苗 股 份」 指 健 倍 苗 苗 股 本 中 每 股 面 值0.01港元的普通股 「主 板」 指 聯 交 所 主 板 「私 營 界 別」 指 非 公 營 界 別 「研 發」 指 研 究 及 開 發 「聯 交 所」 指 香 港 聯 合 交 易 所 有 限 ...

Financial Performance - Total revenue for the fiscal year 2023 reached HKD 1,785,579,000, an increase of 11.9% compared to HKD 1,595,543,000 in the previous year[10] - Non-patent drug revenue grew by 6.4% to HKD 1,267,598,000 from HKD 1,191,360,000[10] - Brand healthcare product revenue surged by 28.2% to HKD 517,981,000 from HKD 404,183,000[10] - Gross profit increased by 20.4% to HKD 747,172,000, with a gross margin of 41.8%, up from 38.9%[10] - Profit attributable to equity holders rose by 41.3% to HKD 251,044,000, with a profit margin of 14.1%, compared to 11.1% in the previous year[10] - Adjusted EBITDA for the year was HKD 568,172,000, reflecting a growth of 28.7% from HKD 441,614,000[10] - The adjusted EBITDA margin improved to 31.8% from 27.7%[10] - Adjusted EBITDA for the fiscal year 2023 reached HKD 500,000,000, showing significant growth compared to previous years[22] - Profit attributable to equity holders for fiscal year 2023 was HKD 250,000,000, reflecting a positive trend[23] - The adjusted EBITDA grew by 28.7%, with the gross profit margin rising from 38.9% to 41.8%[53] - The company reported a total revenue of HKD 1,785.6 million for the fiscal year 2023, representing a 12% increase from HKD 1,595.5 million in the previous year[97] - Yearly profit surged by HKD 95.5 million or 50.9% to HKD 283.2 million, reflecting increased operating profit due to the gradual easing of social distancing and travel restrictions[121] Market and Product Development - The company is focusing on expanding its product pipeline, including the development of new specialty drugs and biosimilars to capture fast-growing markets[2] - The company aims to enhance its R&D capabilities and commercial networks to address unmet medical needs[14] - The company is actively exploring partnerships with local and overseas R&D institutions to develop innovative drug manufacturing technologies[2] - The company aims to enhance its R&D capabilities to develop more affordable complex generics, improving access to essential medicines[20] - The company is focusing on developing chronic disease and high-growth treatment areas to provide affordable healthcare solutions[44] - The company launched 22 new products during the reporting period, including Entecavir Tablet and Olmesartan Tablets[42] - The company plans to introduce a new oral anticoagulant and a novel echinocandin for treating invasive fungal infections, enhancing its product portfolio[89] - The company has successfully obtained exclusive licensing agreements for 53 high-efficiency specialty drugs across various therapeutic areas, including oncology and cardiovascular care[66] Operational Efficiency - Cash generated from operating activities was approximately HKD 677.7 million, supporting capacity-building investments and a proposed final dividend of HKD 0.0238 per share, a 33.5% increase from the previous year[53] - The production of liquid formulations increased by 43.1% to approximately 2 million liters, showcasing the company's ability to respond effectively to market needs[45] - The production of eye drop products grew by 18.1%, reaching over 48,000 liters, while solid oral dosage forms increased by 12.0%, totaling over 3.3 billion capsules and tablets[46] - The company is expanding production capabilities to meet growing market demand, focusing on modernizing equipment and optimizing processes[85] - The company has made significant progress in market access in the Greater Bay Area through strategic collaboration with the Hong Kong University Shenzhen Hospital[87] Financial Position - Total assets increased by 13.1% to HKD 5,380,499,000 as of March 31, 2023[26] - Total liabilities rose by 18.2% to HKD 2,123,977,000 as of March 31, 2023[26] - Total equity grew by 10.1% to HKD 3,256,522,000 as of March 31, 2023[26] - The company reported a cash balance of HKD 1,036.4 million at the end of the reporting period, maintaining a robust cash position[62] - The group's net capital debt ratio decreased from 29.2% as of March 31, 2022, to 15.6% as of March 31, 2023, primarily due to a net cash inflow from operating activities of HKD 677.7 million during the reporting period[141] - Bank loans increased by HKD 202.1 million or 15.1%, primarily due to the acquisition of a syndicated loan for refinancing existing floating-rate bank loans[126] Corporate Governance - The board consists of seven directors, including three executive directors, one non-executive director, and three independent non-executive directors, ensuring a balanced composition[149] - The company has complied with all corporate governance code provisions during the reporting period, except for the separation of the roles of chairman and CEO, which is detailed in the report[146] - The board has established an independence assessment mechanism to ensure strong independent elements, allowing for effective independent judgment[140] - The board is committed to maintaining high standards of corporate governance and has adopted most best practices outlined in the corporate governance code[145] - The company has implemented a written guideline for employees regarding securities trading to ensure compliance with standards[147] Strategic Initiatives - The company has begun supplying a specialized drug to patients at the Hong Kong University Shenzhen Hospital after obtaining regulatory approval, with plans to expand coverage to 14 additional hospitals in the Greater Bay Area[68] - The launch of the e-Jacob Pharma2U digital platform is set for the second half of the year, aimed at enhancing customer service through digital transformation[69] - The company has entered into a strategic partnership with the University of Hong Kong-Shenzhen Hospital to expand into the Greater Bay Area market, which has shown a GDP growth of approximately 7.0% annually over the past decade[93] Employee and Operational Growth - The total number of employees increased to 1,789 as of March 31, 2023, up from 1,736 the previous year, indicating strategic business development and expansion[95] - Employee costs increased by HKD 47.3 million or 11.1%, reflecting the growth in production staff and salary adjustments to support sales growth[102]

[Annual Results Announcement for the Year Ended March 31, 2023](index=1&type=section&id=Annual%20Results%20Announcement) This report presents the annual results of Jacobson Pharma Corporation Limited for the financial year ended March 31, 2023, detailing financial performance, operational highlights, and future outlook [Financial Highlights](index=1&type=section&id=Financial%20Highlights) Jacobson Pharma Corporation Limited achieved significant growth in the financial year ended March 31, 2023, with substantial increases in revenue, operating profit, and profit for the year, alongside proposed final and in-specie special dividends FY2023 Financial Summary | Metric | FY2023 (HK$ million) | FY2022 (HK$ million) | Change (%) | | :----------- | :------------------- | :------------------- | :------- | | Revenue | 1,785.6 | 1,595.5 | +11.9% | | Operating Profit | 410.8 | 260.9 | +57.5% | | Profit for the Year | 283.2 | 187.7 | +50.9% | - The Board recommends a final dividend of **2.38 HK cents per ordinary share** for the year ended March 31, 2023, totaling approximately **HK$46.0 million** (2022: 2.68 HK cents per share)[26](index=26&type=chunk) - Total dividends for the year ended March 31, 2023, amounted to **5.18 HK cents per ordinary share** (2022: 3.88 HK cents per ordinary share)[26](index=26&type=chunk) - The Board also recommends a special dividend in the form of an in-specie distribution of **509 JBM shares for every 2,000 shares** held by the Company's equity holders[26](index=26&type=chunk) [Consolidated Financial Statements](index=2&type=section&id=Consolidated%20Financial%20Statements) This section presents the consolidated financial statements, including the statement of profit or loss, financial position, and related notes, for the reporting period [Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=2&type=section&id=Consolidated%20Statement%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income) For the year ended March 31, 2023, revenue grew by **11.9% to HK$1,785.6 million**, gross profit by **20.4% to HK$747.2 million**, operating profit by **57.5% to HK$410.8 million**, and profit for the year by **50.9% to HK$283.2 million**, driven by revaluation gains on financial assets Key Data from Consolidated Statement of Profit or Loss and Other Comprehensive Income | Metric | 2023 (HK$ thousand) | 2022 (HK$ thousand) | | :------------------- | :-------------- | :-------------- | | Revenue | 1,785,579 | 1,595,543 | | Cost of sales | (1,038,407) | (975,021) | | Gross profit | 747,172 | 620,522 | | Other net income | 91,658 | 40,499 | | Selling and distribution expenses | (196,723) | (184,087) | | Administrative and other operating expenses | (231,347) | (216,046) | | Operating Profit | 410,760 | 260,888 | | Finance costs | (67,445) | (25,687) | | Profit before tax | 339,755 | 231,433 | | Income tax expense | (56,546) | (43,728) | | Profit for the Year | 283,209 | 187,705 | | Other comprehensive income for the year | 108,057 | (25,742) | | Total comprehensive income for the year | 391,266 | 161,963 | | Profit attributable to owners of the Company | 251,044 | 177,666 | | Profit attributable to non-controlling interests | 32,165 | 10,039 | | Basic and diluted earnings per share (HK cents) | 13.13 | 9.27 | [Consolidated Statement of Financial Position](index=4&type=section&id=Consolidated%20Statement%20of%20Financial%20Position) As of March 31, 2023, total assets were **HK$4,724.1 million**, a **20.2% increase** year-on-year, with cash and cash equivalents surging by **116.5% to HK$1,036.4 million**, while net assets grew by **10.1% to HK$3,256.5 million** Key Data from Consolidated Statement of Financial Position | Metric | 2023 (HK$ thousand) | 2022 (HK$ thousand) | | :------------------- | :-------------- | :-------------- | | **ASSETS** | | | | Non-current assets | 3,623,086 | 3,577,295 | | Investment properties | 181,172 | 230,472 | | Property, plant and equipment | 1,502,148 | 1,503,773 | | Intangible assets | 1,320,075 | 1,303,177 | | Interests in associates | 51,821 | 53,929 | | Interests in joint ventures | 3,616 | 4,334 | | Other non-current assets | 39,693 | 58,688 | | Other financial assets | 514,330 | 412,766 | | Deferred tax assets | 10,231 | 10,156 | | Current assets | 1,757,413 | 1,178,245 | | Inventories | 368,003 | 314,557 | | Trade and other receivables | 351,360 | 380,546 | | Current tax recoverable | 1,632 | 4,489 | | Cash and cash equivalents | 1,036,418 | 478,653 | | **LIABILITIES** | | | | Current liabilities | 1,100,978 | 351,861 | | Trade and other payables and contract liabilities | 283,653 | 159,411 | | Non-current liabilities | 1,467,542 | 971,191 | | Bank loans | 1,234,153 | 729,472 | | Lease liabilities | 20,534 | 34,319 | | Deferred tax liabilities | 212,855 | 207,400 | | **EQUITY** | | | | Net assets | 3,256,522 | 2,957,965 | | Total equity attributable to owners of the Company | 2,736,689 | 2,491,316 | | Non-controlling interests | 519,833 | 466,649 | | Total equity | 3,256,522 | 2,957,965 | [Notes to the Consolidated Financial Statements](index=6&type=section&id=Notes%20to%20the%20Consolidated%20Financial%20Statements) This section provides detailed notes and explanations supporting the consolidated financial statements, covering company information, accounting policies, and key financial items [Company Information](index=6&type=section&id=Company%20Information) Jacobson Pharma Corporation Limited is an investment holding company incorporated in the Cayman Islands, primarily engaged in the development, production, marketing, and sale of generic drugs and branded healthcare products, with its shares listed on the Main Board on September 21, 2016 - Jacobson Pharma Corporation Limited is an exempted company incorporated in the Cayman Islands, primarily engaged in the development, production, marketing, and sale of generic drugs and branded healthcare products[15](index=15&type=chunk) - The Company's shares were listed on the Main Board on September 21, 2016[15](index=15&type=chunk) [Basis of Preparation](index=6&type=section&id=Basis%20of%20Preparation) The consolidated financial statements are prepared in accordance with all applicable Hong Kong Financial Reporting Standards and the disclosure requirements of the Hong Kong Companies Ordinance, complying with the Listing Rules, and are presented on a historical cost basis, except for investment properties and financial assets measured at fair value - The consolidated financial statements are prepared in accordance with all applicable Hong Kong Financial Reporting Standards (including all applicable individual HKFRSs, HKASs, and Interpretations issued by the HKICPA) and the disclosure requirements of the Hong Kong Companies Ordinance[17](index=17&type=chunk) - These financial statements also comply with the applicable disclosure provisions of the Listing Rules[17](index=17&type=chunk) - The Group's consolidated financial statements are prepared on a historical cost basis, except for investment properties and investments measured at fair value through other comprehensive income and fair value through profit or loss, which are presented at fair value[38](index=38&type=chunk) [Changes in Accounting Policies](index=6&type=section&id=Changes%20in%20Accounting%20Policies) During this accounting